121 257

Cited 17 times in

Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.

Authors
 Jung Wook Huh  ;  Yoon Ah Park  ;  Kang Young Lee  ;  Seung-Kook Sohn 
Citation
 YONSEI MEDICAL JOURNAL, Vol.50(5) : 697-703, 2009 
Journal Title
YONSEI MEDICAL JOURNAL
ISSN
 0513-5796 
Issue Date
2009
MeSH
Adenocarcinoma/drug therapy* ; Adenosine Triphosphate/metabolism* ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology* ; Antineoplastic Agents/therapeutic use ; Colorectal Neoplasms/drug therapy* ; Drug Screening Assays, Antitumor/methods* ; Female ; Humans ; Male ; Middle Aged ; Precision Medicine ; Tumor Cells, Cultured
Keywords
Adenosine triphosphate ; chemotherapy response assay ; colorectal cancer
Abstract
PURPOSE: Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology that can individualize chemotherapy for patients with lung, stomach, or breast cancer. This study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer. MATERIALS AND METHODS: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA. We calculated the cell death rate (CDR) by measuring intracellular ATP levels of drug-exposed cells and untreated controls. RESULTS: Interpretable results were available for 85.5% (118/138) of patients. The mean coefficient of variation for triplicate ATP measurements was 9.2%. The highest CDR was observed in irinotecan (34.0%) and the lowest CDR in etoposide (21.0%). Paclitaxel had the broadest range of CDR (0-86.7%) and 5-FU had the narrowest range of CDR (0-56.8%). The overall highest responsiveness was seen most prevalently in irinotecan (24.7%, 23/93 patients). Irinotecan had the greatest responsiveness in patients with well differentiated and moderately differentiated carcinoma. CONCLUSION: Our study suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment with a specific chemotherapeutic agent.
Files in This Item:
T200905808.pdf Download
DOI
10.3349/ymj.2009.50.5.697
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Park, Yoon Ah(박윤아)
Sohn, Seung Kook(손승국)
Lee, Kang Young(이강영)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/105917
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links